Health authorities in the Democratic Republic of Congo (DRC) Democratic Republic of the Congo confirmed 246 suspected Ebola cases and 80 deaths on Saturday, marking the latest in a series of deadly outbreaks in the country. The current strain, Bundibugyo ebolavirus, has no approved vaccine and carries a high mortality rate, according to Health Minister Samuel-Roger Kamba Samuel-Roger Kamba during a press briefing in Kinshasa. The minister did not specify the timeline for the outbreak’s start but noted the situation remains under close monitoring by national and international health agencies.

No vaccine available for lethal strain

The Bundibugyo strain, first identified in Uganda in 2007, has caused severe illness in previous outbreaks, with fatality rates exceeding 50% in some cases. Unlike the more widely known Zaire ebolavirus, for which multiple vaccines exist, Bundibugyo lacks a dedicated immunization strategy. The World Health Organization World Health Organization has classified it as a priority pathogen due to its high lethality and potential for rapid spread in densely populated areas. Local health workers are relying on isolation and supportive care as primary interventions.

DRC health officials reported cases concentrated in eastern provinces, a region already grappling with multiple health crises, including malaria and cholera. The outbreak’s location raises concerns about the strain’s spread into neighboring countries, where healthcare systems remain under strain. International health groups, including Médecins Sans Frontières Médecins Sans Frontières, have deployed teams to support containment efforts. Surveillance and contact tracing are underway, but challenges persist due to limited resources and logistical hurdles in remote areas.

Previous outbreaks and lessons learned

This is not the first time Bundibugyo has surfaced in DRC. The country experienced a major outbreak in 2012, which resulted in 57 cases and 29 deaths. Lessons from past responses have informed the current strategy, including the rapid deployment of rapid diagnostic tests and the establishment of treatment centers. However, the absence of a vaccine complicates efforts to curb transmission, leaving communities vulnerable to further spread.

The health minister acknowledged the strain’s severity and urged the public to adhere to preventive measures, including avoiding contact with sick individuals and reporting suspected cases immediately. Local leaders have intensified community awareness campaigns to combat misinformation and encourage early medical intervention. The government has also requested additional support from global health partners to address the outbreak’s challenges.

International health experts warn that the current outbreak could escalate if containment measures fail. The DRC’s ongoing conflicts and weak healthcare infrastructure further exacerbate the risks. The World Health Organization and other agencies are coordinating with Kinshasa to secure funding and resources for a sustained response. Experts emphasize the need for global solidarity to prevent a wider regional or international health emergency.

The situation remains fluid, with health officials updating case counts and response efforts daily. Authorities have not yet declared the outbreak a public health emergency of international concern under the International Health Regulations, but the risk of escalation is being closely evaluated. The next two weeks will be critical in determining whether the outbreak can be contained or if further measures will be required.

What You Need to Know

  • Source: France 24
  • Published: May 16, 2026 at 15:02 UTC
  • Category: World
  • Topics: #france24 · #world-news · #europe · #war · #conflict · #ebola

Read the Full Story

This is a curated summary. For the complete article, original data, quotes and full analysis:

Read the full story on France 24 →

All reporting rights belong to the respective author(s) at France 24. GlobalBR News summarizes publicly available content to help readers discover the most relevant global news.

Curated by GlobalBR News · May 16, 2026

🇧🇷 Resumo em Português

O surto de Ebola no leste da República Democrática do Congo (RDC) deixa um rastro de 80 mortos entre 246 casos suspeitos, com a agência de saúde local alertando para a gravidade do cenário. A doença, causada pela cepa Bundibugyo — uma das mais letais e para a qual ainda não existe vacina —, ameaça se espalhar em uma região já fragilizada por conflitos armados e falta de infraestrutura médica.

O Brasil, embora não registre casos da doença recentemente, precisa acompanhar de perto a evolução do surto, especialmente por conta da conectividade global e do histórico de transmissão do Ebola em outras crises africanas. A ausência de imunizantes contra essa cepa específica reforça a importância da vigilância sanitária brasileira, que já mantém protocolos rígidos de biossegurança em portos e aeroportos. Além disso, a situação na RDC evidencia os desafios dos sistemas de saúde em países de baixa renda, um tema que interessa diretamente ao público brasileiro, que acompanha debates sobre o financiamento da saúde pública.

A Organização Mundial da Saúde (OMS) já iniciou discussões emergenciais para conter a propagação, enquanto a comunidade internacional corre contra o tempo para desenvolver uma solução.

🇪🇸 Resumen en Español

La República Democrática del Congo afronta una nueva y letal oleada de ébola con un balance provisional de 80 fallecidos entre 246 casos sospechosos, mientras el mundo carece aún de una vacuna efectiva contra la cepa Bundibugyo, una variante especialmente virulenta.

Este brote, que se suma a la larga lista de emergencias sanitarias que asolan regiones remotas de África central, subraya la urgencia de reforzar los sistemas de vigilancia y respuesta rápida en zonas con infraestructuras sanitarias frágiles. Para los hispanohablantes, la noticia recuerda la importancia de la cooperación internacional en salud pública, pues enfermedades como el ébola no conocen fronteras y su expansión podría convertirse en una amenaza global. Además, evidencia la necesidad de invertir en investigación científica para desarrollar tratamientos y vacunas accesibles en contextos de pobreza extrema, donde el acceso a medicamentos sigue siendo un lujo.